Inhaled Treprostinil

DRUG15 trials

Sponsors

United Therapeutics, Inova Health Care Services, University of Florida, Ferrer Internacional S.A., University of California, San Diego

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Combined Pulmonary Fibrosis and EmphysemaIdiopathic Pulmonary FibrosisInterstitial Lung DiseasePrecapillary Pulmonary HypertensionProgressive Pulmonary FibrosisPulmonary Arterial Hypertension

Early Phase 1

Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension

Not yet recruitingNCT07116681

University of California, San DiegoPulmonary Hypertension

Start: 2025-10-01End: 2027-07-01Target: 8Updated: 2025-08-24

Phase 2

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

TerminatedNCT02178566

Inova Health Care ServicesChronic Obstructive Pulmonary Disease (COPD)

Start: 2015-08-31End: 2019-01-31Updated: 2022-04-12

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

CompletedNCT02630316

United TherapeuticsCombined Pulmonary Fibrosis and Emphysema, Interstitial Lung Disease, Pulmonary Hypertension

Start: 2017-02-03End: 2019-12-26Updated: 2022-07-27

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

TerminatedNCT02633293

United TherapeuticsCombined Pulmonary Fibrosis and Emphysema, Interstitial Lung Disease, Pulmonary Hypertension

Start: 2016-09-15End: 2021-08-01Updated: 2022-12-02

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

WithdrawnNCT03012646

United TherapeuticsChronic Obstructive Pulmonary Disease, Pulmonary Hypertension

Start: 2017-04-30End: 2019-04-30Updated: 2017-04-11

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

CompletedNCT03814317

University of FloridaInterstitial Lung Disease, Precapillary Pulmonary Hypertension, Sarcoidosis

Start: 2020-01-30End: 2025-12-31Updated: 2026-02-06

Phase 3

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

CompletedNCT00147199

United TherapeuticsPulmonary Hypertension

Start: 2005-06-30End: 2007-10-31Updated: 2024-01-02

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

WithdrawnNCT01557647

United TherapeuticsPulmonary Arterial Hypertension

Start: 2012-06-30End: 2016-06-30Updated: 2012-03-26

Inhaled Treprostinil for PAH: Open-label Extension

WithdrawnNCT01557660

United TherapeuticsPulmonary Arterial Hypertension

Start: 2012-06-30End: 2018-12-31Updated: 2012-03-26

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

CompletedNCT04708782

United TherapeuticsIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease

Start: 2021-06-01End: 2026-02-02Updated: 2026-02-10

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Enrolling by invitationNCT04905693

United TherapeuticsIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

Start: 2022-09-06End: 2026-06-01Target: 1850Updated: 2026-03-31

Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

CompletedNCT05255991

United TherapeuticsIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease

Start: 2022-10-04End: 2025-06-30Updated: 2025-08-15

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

RecruitingNCT05943535

United TherapeuticsInterstitial Lung Disease, Progressive Pulmonary Fibrosis

Start: 2023-10-30End: 2027-11-01Target: 698Updated: 2026-03-31

Phase 4

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

CompletedNCT00741819

United TherapeuticsPulmonary Arterial Hypertension

Start: 2008-09-30End: 2010-12-31Updated: 2013-02-20

Unknown Phase

Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

Ferrer Internacional S.A.Combined Pulmonary Fibrosis and Emphysema, Interstitial Lung Disease, Pulmonary Hypertension

Updated: 2022-10-10

Related Papers

Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.

2026-03-11

TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis: Preliminary Baseline Demographics

American Journal of Respiratory and Critical Care Medicine2025-05-011 citations

Teton Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis: Annual Update of Preliminary Baseline Data

American Journal of Respiratory and Critical Care Medicine2025-05-01

A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema.

2024-01-182 citations

Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.

2022-09-1531 citations

Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis

BMJ Open Respiratory Research2022-07-0157 citations

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.

2021-06-29102 citations

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

New England Journal of Medicine2021-01-13555 citations

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

2010-05-01386 citations